GSK and Janssen wade into competitive RA market with Phase III sirukumab program
This article was originally published in Scrip
GlaxoSmithKline and Janssen Biologics kicked off the Phase III program for their interleukin-6 (IL-6) inhibitor sirukumab (CNTO 136), which would compete with relative newcomers in the competitive rheumatoid arthritis market – Genentech's Actemra (tocilizumab), the first IL-6 inhibitor approved to treat patients with moderately to severely active rheumatoid arthritis, and Pfizer's novel oral Janus kinase (JAK) inhibitor tofacitinib.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.